

hepatoSIGHT.



Pricing

1. Introduction to hepatoSIGHT®

hepatoSIGHT® is a powerful, easy to use tool that enables clinicians to identify cohorts of patients with user-defined patterns of blood test abnormalities. It is a highly flexible tool that allows the user to specify parameters indicative of potential liver disease and set thresholds for these parameters to flexibly risk stratify the population.

This tool allows rapid, user defined searches of a large database of pre-existing blood tests (currently 600,000 individuals, 205 million tests). The system is designed so that it can be expanded; ultimately to cover the whole of the country's population. hepatoSIGHT® includes data to target deprivation, and to accurately map cohort sizes before they are generated. These features allow targeted evaluation and intervention within specific populations.

The system can review 100s of millions of lines of data within seconds based on patterns of abnormalities and thresholds set by the healthcare team, finding patients who meet specified criteria. It is an intuitive, easy-to-use system that rapidly risk stratifies the population and identifies individuals who will benefit from intervention. It is also an effective tool for identifying cohorts of patients for potential enrolment in research studies. This system is secure and allows the frontline healthcare team to interrogate hundreds of thousands of patient records to create manageable cohorts for intervention in seconds.

hepatoSIGHT® supports the identification of for longitudinal trends over time – e.g. trends, integrals, maxima and minima etc. This approach has been shown to be extremely powerful, with an odds ratio for the detection of liver disease > 18 in preliminary tests (Wesley E, Matull W, Kitchin A, et al - A cumulative liver damage index (CLDI) identifies patients at risk of significant liver disease Gut 2022;71:A4).

hepatoSIGHT® has been in use in Somerset since early 2023 and is routinely used to find people most at risk of liver disease. In the first year, over 700 people have been contacted and invited to make an appointment in the liver clinic for further investigation, none of whom were already under the care of a liver specialist.

2. Pricing structure

The licencing structure for hepatoSIGHT® is based on three licence tiers as follows:

- Tier 1 – single purpose. This would be to support a specific project with a clearly defined outcome, such as one which might be used to support a single research project. This Tier will be time limited.
- Tier 2 – general purpose. This Tier would be for a client to use to support casefinding for risk stratification for treatment and non-commercial Research and Development. Clients will have flexibility to use the hepatoSIGHT® solution for any such casefinding.
- Tier 3 – Commercial trials. This Tier would be provided to clients to support casefinding to generate research for clinical trials. Licences will be available in units of 5 (to support up to 5 commercial trials) and users will be required to record which trial a given search is being made to support. Each trial would be subject to Research and Ethics approval prior to the trial being added to hepatoSIGHT® as a drop-down option.

3. Costs

Licence type	Implementation and year 1	Annual cost from year 2
Tier 1 – single purpose	0.20p per head of population	0.10p per head of population
Tier 2 – general purpose	0.20p per head of population (unless already implemented, in which case no additional cost)	0.10p per head of population
Tier 3 – commercial trial casefinding (up to 5 trials)	0.20p per head of population (unless already implemented, in which case no additional cost)	0.5p to 0.15p per head of population depending on complexity and scale

Costs are subject to an increase each year on 1st April which will be no more than the Retail Price Index (RPI).

Neil Stevens
Managing Director
28th January 2026